Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Pyme británica ofrece una nueva pequeña molécula con actividad específica para el tratamiento de la fibrosis

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20180413003
Publicado:
03/05/2018
Caducidad:
04/05/2019
Resumen:
Una pyme británica ha desarrollado una nueva pequeña molécula que se dirige específicamente a la ROCK2, una proteína que desempeña un papel fundamental en la fibrosis. Esta molécula tiene una potente afinidad contra la proteína ROCK2 y, debido a su especificidad, se espera que tenga un buen perfil de seguridad. El objetivo es evitar los efectos secundarios de hipotensores relacionados generalmente con los inhibidores pan-ROCK. La empresa busca compañías farmacéuticas para continuar con el desarrollo y comercializar posteriormente la molécula en el marco de un acuerdo de licencia o cooperación técnica.

Details

Tittle:
UK-based SME offers a novel small molecule with specific activity being developed for treatment of fibrosis
Summary:
A UK-based SME is developing a novel small molecule that specifically targets ROCK2, a protein that plays a key role in fibrosis. This molecule has potent affinity for ROCK 2 and due to its specificity is expected to have a good safety profile. The SME is looking to partner with other pharmaceutical companies for further development of this molecule leading ultimately to commercialisation. The partnership is expected to take the form of either a licensing agreement or a technical cooperation.
Description:
Several diseases result in fibrosis, which can cause ´scarring´ of tissues that affect their function, resulting in pathology and adverse effects for patients. Such diseases include idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis and diabetic nephropathy where the effect of this fibrosis can be serious and even life threatening. New treatments that can prevent or even reverse fibrosis are therefore needed.

A UK-based SME has developed a novel small molecule that selectively targets ROCK2 (Rho-associated coiled-coil-containing protein kinase 2). ROCK2 signalling plays a key role in both the inflammatory component and the fibrotic re-modelling that drives disease progression. This small molecule is being developed as a highly selective agent with subnanomolar affinity against ROCK2. By selectively targeting ROCK2, the SME aims to avoid the hypotensive side effects typically associated with systemic pan-ROCK inhibitors. Their small molecule is therefore expected to show an improved safety profile over other inhibitors.

The SME is offering access to both the small molecule and the data generated in the development programme so far to other pharmaceutical companies for further development leading to commercialisation. It is expected that the partnership will either be a licensing agreement or a technical cooperation depending in specific circumstances.
Advantages and Innovations:
The SMEs novel small molecule has the following advantages:

High degree of specificity against the target protein.

Potent efficacy - in the nano-molar region.

Good safety - the high level of specificity and potent efficacy expected to avoid the low blood pressure seen with other non-specific ROCK inhibitors.
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how,Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The SME is looking to partner with other companies in the pharmaceutical sector and in particular those with interests in fibrosis and fibrotic diseases such as idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis and diabetic nephropathy.

The SME will provide access to the novel small molecule and date generated to date to a partner for further development and ultimately commercialisation. It is expected that the partnership will take the form of a licensing agreement or a technical cooperation dependant on the situation.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos